LYELL IMMUNOPHARMA INC (LYEL) Institutional Ownership
None of the superinvestors we track currently report LYELL IMMUNOPHARMA INC (LYEL) in their latest SEC Form 13F filings.
13F filings cover institutional equity holdings and are reported quarterly with a delay. This stock may still have insider Form 4 activity or appear in future filings.
When tracked funds report positions in LYELL IMMUNOPHARMA INC (LYEL), this page will show asset manager ownership trends, hedge fund exposure, portfolio concentration, historical 13F filings, and estimated holding performance.
Institutional Ownership Trend
| Portfolio quarter | Institutional holders | Total reported value | Total shares |
|---|---|---|---|
| Q1 2025 | 1 | $951,453 | 1,768,500 |
| Q4 2024 | 1 | $1,031,773 | 1,612,146 |
| Q3 2024 | 1 | $272,412 | 197,400 |
| Q2 2024 | 1 | $220,835 | 152,300 |
| Q1 2024 | 1 | $944 | 423,500 |
| Q4 2023 | 1 | $141 | 72,500 |
| Q3 2022 | 1 | $298 | 40,700 |
| Q2 2022 | 1 | $327 | 50,200 |
| Q1 2022 | 1 | $270 | 53,500 |
Related LYEL Institutional Insights:
- LYEL Institutional Ownership & Insiders Activity
- LYEL Institutional Ownership & 13F Activity
- LYEL Top Institutional Shareholders
- LYEL Institutional Buying Activity
- LYEL Institutional Selling Activity
- Institutional Portfolio Overlap & Shared Holdings
- LYEL Insider Trading & SEC Form 4 Activity
- Top Institutional Investor Stock Rankings